Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hicham Skali, M.D.

Co-Author

This page shows the publications co-authored by Hicham Skali and Marc Pfeffer.
Connection Strength

3.311
  1. PRAISE (prospective randomized amlodipine survival evaluation) and criticism. JACC Heart Fail. 2013 Aug; 1(4):315-317.
    View in: PubMed
    Score: 0.570
  2. Are we asking too much of our trials? Am Heart J. 2002 Jan; 143(1):1-3.
    View in: PubMed
    Score: 0.255
  3. Prospects for ARB in the next five years. J Renin Angiotensin Aldosterone Syst. 2001 Dec; 2(4):215-8.
    View in: PubMed
    Score: 0.254
  4. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014 May; 16(5):560-5.
    View in: PubMed
    Score: 0.148
  5. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. J Heart Lung Transplant. 2014 Apr; 33(4):372-81.
    View in: PubMed
    Score: 0.147
  6. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
    View in: PubMed
    Score: 0.136
  7. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. 2012 Feb; 1(1):8-15.
    View in: PubMed
    Score: 0.129
  8. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.127
  9. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J. 2011 Sep; 162(3):548-54.
    View in: PubMed
    Score: 0.124
  10. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart Rhythm. 2007 Mar; 4(3):308-13.
    View in: PubMed
    Score: 0.090
  11. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation. 2006 Nov 21; 114(21):2298-303.
    View in: PubMed
    Score: 0.090
  12. Prognostic use of echocardiography 1 year after a myocardial infarction. Am Heart J. 2005 Oct; 150(4):743-9.
    View in: PubMed
    Score: 0.083
  13. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005 Jun 28; 111(25):3411-9.
    View in: PubMed
    Score: 0.081
  14. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med. 2004 Nov 08; 164(20):2273-9.
    View in: PubMed
    Score: 0.078
  15. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004 Oct 12; 110(15):2180-3.
    View in: PubMed
    Score: 0.077
  16. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004 Sep 21; 110(12):1572-8.
    View in: PubMed
    Score: 0.077
  17. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. Eur J Heart Fail. 2020 07; 22(7):1133-1143.
    View in: PubMed
    Score: 0.056
  18. Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. Eur Stroke J. 2016 Jun; 1(2):93-100.
    View in: PubMed
    Score: 0.043
  19. Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. Eur Heart J. 2016 Feb 01; 37(5):466-72.
    View in: PubMed
    Score: 0.042
  20. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J Hum Hypertens. 2016 Jan; 30(1):46-52.
    View in: PubMed
    Score: 0.040
  21. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2015 Mar; 17(3):301-12.
    View in: PubMed
    Score: 0.040
  22. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. Eur Heart J. 2015 Mar 14; 36(11):669-75.
    View in: PubMed
    Score: 0.039
  23. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Res Care. 2014; 2(1):e000011.
    View in: PubMed
    Score: 0.037
  24. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012 May 15; 59(20):1785-95.
    View in: PubMed
    Score: 0.033
  25. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012 Feb; 14(2):185-92.
    View in: PubMed
    Score: 0.031
  26. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J. 2011 Oct; 162(4):685-91.
    View in: PubMed
    Score: 0.031
  27. Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. Am Heart J. 2011 Jun; 161(6):1156-62.
    View in: PubMed
    Score: 0.031
  28. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 May; 32(10):1227-34.
    View in: PubMed
    Score: 0.030
  29. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010 Aug 10; 122(6):597-602.
    View in: PubMed
    Score: 0.029
  30. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008 Sep; 1(5):582-91.
    View in: PubMed
    Score: 0.025
  31. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol. 2008 Mar 01; 101(5):607-12.
    View in: PubMed
    Score: 0.024
  32. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Am Heart J. 2008 Apr; 155(4):706-11.
    View in: PubMed
    Score: 0.024
  33. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007 Sep 25; 116(13):1482-7.
    View in: PubMed
    Score: 0.024
  34. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Aug 07; 116(6):627-36.
    View in: PubMed
    Score: 0.023
  35. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. Eur Heart J. 2007 Feb; 28(3):326-33.
    View in: PubMed
    Score: 0.023
  36. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. J Am Soc Echocardiogr. 2006 Dec; 19(12):1462-5.
    View in: PubMed
    Score: 0.022
  37. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006 Oct; 17(10):2886-91.
    View in: PubMed
    Score: 0.022
  38. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1725-7.
    View in: PubMed
    Score: 0.021
  39. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm. 2006 Mar; 3(3):313-6.
    View in: PubMed
    Score: 0.021
  40. Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience. J Am Soc Echocardiogr. 2006 Jan; 19(1):28-33.
    View in: PubMed
    Score: 0.021
  41. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005 Dec 13; 112(24):3738-44.
    View in: PubMed
    Score: 0.021
  42. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J. 2005 Aug; 150(2):257-62.
    View in: PubMed
    Score: 0.020
  43. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004 Dec 14; 110(24):3667-73.
    View in: PubMed
    Score: 0.020
  44. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. J Am Coll Cardiol. 2004 Jun 02; 43(11):2015-21.
    View in: PubMed
    Score: 0.019
  45. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002 Sep 03; 106(10):1251-5.
    View in: PubMed
    Score: 0.017
  46. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002 May 01; 39(9):1450-5.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.